首頁 > 市場調查報告書 > 醫療設備

整形外科

關節內粘稠補充療法市場規模、佔有率和成長分析（按產品、應用、來源、最終用戶和地區分類）—產業預測，2025-2032年

市場調查報告書

商品編碼

1878017

關節內粘稠補充療法市場規模、佔有率和成長分析（按產品、應用、來源、最終用戶和地區分類）—產業預測，2025-2032年

Viscosupplementation Market Size, Share, and Growth Analysis, By Product (Introduction, Single Injection), By Application (Introduction, Knee Osteoarthritis), By Source, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年11月18日 | 出版商:

SkyQuest | 英文 183 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球關節內粘稠補充療法市場預計到 2024 年將達到 51 億美元，到 2025 年將達到 53.8 億美元，到 2033 年將達到 82.6 億美元，預測期（2026-2033 年）的複合年成長率為 5.5%。

全球關節內粘稠補充療法市場正經歷強勁成長，這主要得益於骨關節炎發病率的上升，尤其是在老年人群中。隨著對非侵入性治療方法需求的不斷成長，關節內粘稠補充療法已成為延緩關節重建手術的首選方案。透明質酸配方技術的進步以及微創技術的普及正在推動市場滲透。對維持身體機能的重視、人口老化加劇以及運動傷害的增加進一步推動了市場的動態。然而，高昂的治療費用、保險覆蓋範圍的限制以及不同病患小組療效的差異等挑戰，仍然是市場擴張的重要障礙。此外，替代療法的存在以及各地法規和政策的差異，也可能進一步加劇該領域市場發展的複雜性。

推動全球關節內粘稠補充療法市場發展的因素

全球關節內粘稠補充療法市場的主要促進因素是老年人口中骨關節炎及相關關節疾病盛行率的不斷上升。隨著人們壽命延長和生活方式日益活躍，對有效疼痛管理方案（例如關節內粘稠補充療法療法）的需求也日益成長。這些注射療法透過增加關節潤滑和緩衝作用來緩解疼痛，從而改善活動能力和生活品質。此外，人們健康意識的增強以及對微創治療方法的偏好也促進了市場擴張，因為患者和醫療保健提供者越來越傾向於尋求傳統手術干預之外的關節健康維護方法。

限制全球關節內粘稠補充療法市場發展的因素

全球關節內粘稠補充療法市場的主要限制因素之一是透明質酸類產品核准中日益嚴格的審查和監管挑戰。隨著醫療監管機構收緊臨床療效和安全性標準，企業面臨越來越大的壓力，需要證明關節內粘稠補充療法療法在治療骨關節炎及相關疾病方面的長期療效。這種嚴格的核准流程可能導致產品上市延遲，研發成本增加，進而抑制創新，限制病患獲得新的治療選擇。此外，報銷政策的不確定性也會阻礙醫療機構和病患的接受度。

關節內粘稠補充療法市場的全球趨勢

全球關節內粘稠補充療法市場正經歷著向單次注射和長效製劑的顯著轉變，這主要受便捷高效治療方法需求成長的驅動。患者和醫療服務提供者越來越傾向於選擇單次注射的透明質酸療法，這種療法可以減少就診時間和手術風險，從而提高患者的依從性。同時，長效製劑的推出可望透過持續潤滑關節和緩解疼痛來改善治療效果。這一趨勢反映了門診護理的更廣泛變革，強調在骨關節炎治療中採用更具成本效益的方法，同時滿足患者對微創、高效治療方案日益成長的需求。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Sanofi SA（France）
Anika Therapeutics, Inc.（United States）
SEIKAGAKU CORPORATION（Japan）
Zimmer Biomet Holdings, Inc.（United States）
Bioventus Inc.（United States）
Fidia Farmaceutici SpA（Italy）
Ferring Pharmaceuticals（Switzerland）
Johnson & Johnson（United States）
Smith & Nephew plc（United Kingdom）
Avanos Medical, Inc.（United States）
LG Chem, Ltd.（South Korea）
IBSA Institut Biochimique SA（Switzerland）
Hoffmann-La Roche Ltd.（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
Viatris Inc.（United States）
Lifecore Biomedical, LLC（United States）
Aptissen SA（Switzerland）
Chugai Pharmaceutical Co., Ltd.（Japan）
Kolon TissueGene, Inc.（South Korea）
TRB CHEMEDICA SA（Switzerland）

結論與建議

簡介目錄

Product Code: SQMIG35B2276

Global Viscosupplementation Market size was valued at USD 5.1 billion in 2024 and is poised to grow from USD 5.38 billion in 2025 to USD 8.26 billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global viscosupplementation market is witnessing robust growth, propelled by the rising incidence of osteoarthritis, particularly among the elderly population. As demand for non-invasive treatments surges, viscosupplementation has become a preferred option for delaying joint replacement surgeries. Advances in hyaluronic acid formulations and a shift toward minimally invasive techniques are enhancing market adoption. The emphasis on maintaining physical mobility, coupled with an increasing elderly demographic and a rise in sports-related injuries, is further boosting market dynamics. However, challenges such as high treatment costs, reimbursement hurdles, and variability in effectiveness across different patient groups pose significant barriers to market expansion. Additionally, the presence of alternative treatments and varying regional regulations and reimbursement policies can further complicate market development in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Viscosupplementation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Viscosupplementation Market Segments Analysis

Global Viscosupplementation Market is segmented by Product, Application, Source, End User and region. Based on Product, the market is segmented into Introduction, Single Injection, Three Injection and Five Injection. Based on Application, the market is segmented into Introduction, Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis and Other Applications. Based on Source, the market is segmented into Introduction, Animal Source and Non-Animal Source. Based on End User, the market is segmented into Introduction, Hospitals, Orthopedic Clinics/Ambulatory Surgical Centers (ASCS), Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Viscosupplementation Market

A key market driver for the global viscosupplementation market is the increasing prevalence of osteoarthritis and related joint disorders among the aging population. As individuals live longer and maintain more active lifestyles, the demand for effective pain management solutions, such as viscosupplements, grows. These injectable treatments provide relief by enhancing joint lubrication and cushioning, thus improving mobility and quality of life. Additionally, rising health awareness and a shift toward minimally invasive treatment options contribute to the market's expansion, as patients and healthcare providers seek alternatives to traditional surgical interventions for joint health.

Restraints in the Global Viscosupplementation Market

One significant market restraint for the global viscosupplementation market is the increasing scrutiny and regulatory challenges associated with the approval of hyaluronic acid-based products. As healthcare authorities strengthen their standards for clinical efficacy and safety, companies face heightened pressure to demonstrate the long-term benefits of viscosupplements in treating osteoarthritis and related conditions. This rigorous approval process can lead to delays in product launches and increased costs for research and development, potentially stifling innovation and limiting the availability of new treatment options for patients. Moreover, the uncertainty surrounding reimbursement policies may hinder adoption among healthcare providers and patients alike.

Market Trends of the Global Viscosupplementation Market

The Global Viscosupplementation market is experiencing a significant shift towards single-injection and long-acting formulations, driven by the increasing preference for convenient and efficient treatment options. Patients and healthcare providers are gravitating towards single-injection hyaluronic acid therapies due to their reduced clinic time and procedural risks, enhancing patient compliance. Simultaneously, the introduction of long-acting formulations offers extended joint lubrication and pain relief, leading to improved treatment outcomes. This trend reflects broader changes in outpatient care, highlighting a cost-effective approach to managing osteoarthritis and catering to the growing demand for less invasive and more effective therapeutic solutions.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment

Global Viscosupplementation Market Size by Product & CAGR (2026-2033)

Market Overview
Introduction
Single Injection
Three Injection
Five Injection

Global Viscosupplementation Market Size by Application & CAGR (2026-2033)

Market Overview
Introduction
Knee Osteoarthritis
Hip Osteoarthritis
Shoulder Osteoarthritis
Other Applications

Global Viscosupplementation Market Size by Source & CAGR (2026-2033)

Market Overview
Introduction
Animal Source
Non-Animal Source

Global Viscosupplementation Market Size by End User & CAGR (2026-2033)

Market Overview
Introduction
Hospitals
Orthopedic Clinics/Ambulatory Surgical Centers (ASCS)
Retail Pharmacies
Online Pharmacies

Global Viscosupplementation Market Size & CAGR (2026-2033)

North America (Product, Application, Source, End User)
- US
- Canada
Europe (Product, Application, Source, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Application, Source, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Application, Source, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Application, Source, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Anika Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEIKAGAKU CORPORATION (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zimmer Biomet Holdings, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bioventus Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fidia Farmaceutici S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith & Nephew plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avanos Medical, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LG Chem, Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IBSA Institut Biochimique SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lifecore Biomedical, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aptissen SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chugai Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kolon TissueGene, Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TRB CHEMEDICA SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments